Market closedNon-fractional
ChromaDex/CDXC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ChromaDex
Ticker
CDXC
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Los Angeles, United States
Employees
106
Website
www.chromadex.com
ChromaDex Metrics
BasicAdvanced
$190M
Market cap
-
P/E ratio
-$0.05
EPS
1.96
Beta
-
Dividend rate
Price and volume
Market cap
$190M
Beta
1.96
Financial strength
Current ratio
2.518
Quick ratio
1.795
Long term debt to equity
8.169
Total debt to equity
11.143
Management effectiveness
Return on assets (TTM)
-5.06%
Return on equity (TTM)
-12.39%
Valuation
Price to revenue (TTM)
2.266
Price to book
6.5
Price to tangible book (TTM)
6.61
Price to free cash flow (TTM)
42.538
Growth
Revenue change (TTM)
7.52%
Earnings per share change (TTM)
-66.53%
3-year revenue growth
11.75%
3-year earnings per share growth
-47.05%
What the Analysts think about ChromaDex
Analyst Ratings
Majority rating from 3 analysts.
ChromaDex Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$22M
4.74%
Net income
-$400K
-500.00%
Profit margin
-1.80%
-482.98%
ChromaDex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.01
-
-$0.01
-
Expected
-$0.04
-$0.03
-$0.03
-$0.02
-$0.02
Surprise
-20.00%
-69.23%
-
-40.00%
-
ChromaDex News
AllArticlesVideos
ChromaDex: Looking To Take The Big Step Into Pharma
Seeking Alpha·1 week ago
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
Business Wire·2 weeks ago
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ChromaDex stock?
ChromaDex (CDXC) has a market cap of $190M as of July 06, 2024.
What is the P/E ratio for ChromaDex stock?
The price to earnings (P/E) ratio for ChromaDex (CDXC) stock is 0 as of July 06, 2024.
Does ChromaDex stock pay dividends?
No, ChromaDex (CDXC) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next ChromaDex dividend payment date?
ChromaDex (CDXC) stock does not pay dividends to its shareholders.
What is the beta indicator for ChromaDex?
ChromaDex (CDXC) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell ChromaDex stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.